Skip to content

Press Releases and Events

PRESS RELEASES AND EVENTS

Events

There are currently no events to display.

Archived Events

There are currently no events to display.

Press Releases

Date Title and Summary View
Toggle Summary Intra-Cellular Therapies Initiates Rolling Submission of New Drug Application for Lumateperone for Treatment of Schizophrenia
NEW YORK , June 06, 2018 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced the initiation of a rolling submission of its New Drug Application (NDA) with
View HTML
Toggle Summary Intra-Cellular Therapies Presents Data on Symptom Improvement by Lumateperone on Negative Symptoms, Depression, and Social Function in Patients with Schizophrenia at the American Society of Clinical Psychopharmacology (ASCP) Annual Meeting
NEW YORK , May 31, 2018 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, announced presentations on lumateperone at the American Society of Clinical Psychopharmacology
View HTML
Toggle Summary Intra-Cellular Therapies to Present at the Jefferies 2018 Global Healthcare Conference
NEW YORK , May 30, 2018 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system ("CNS") disorders, today announced that Sharon Mates , Ph.D., Chief Executive Officer and Chairman, is
View HTML
Toggle Summary Intra-Cellular Therapies Announces Presentations on Lumateperone at the American Society of Clinical Psychopharmacology (ASCP) Annual Meeting
NEW YORK , May 29, 2018 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, announced poster presentations at the upcoming American Society of Clinical Psychopharmacology
View HTML
Toggle Summary Intra-Cellular Therapies to Present at the Bank of America Merrill Lynch 2018 Health Care Conference
NEW YORK , May 09, 2018 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system ("CNS") disorders, today announced that Sharon Mates , Ph.D., Chief Executive Officer and Chairman, is
View HTML
Toggle Summary Intra-Cellular Therapies Announces Presentations on Lumateperone at Two Upcoming Medical Conferences
NEW YORK , May 04, 2018 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, announced presentations on lumateperone at the 2018 American Psychiatric Association (APA)
View HTML
Toggle Summary Intra-Cellular Therapies Reports First Quarter 2018 Financial Results and Provides Corporate Update
NEW YORK , May 03, 2018 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced its financial results for the first quarter ended March 31, 2018 and provided
View HTML
Toggle Summary Intra-Cellular Therapies Presents Data on ITI-214 at the 2018 American Academy of Neurology Annual Meeting
Phase 1/2 clinical trial in patients with Parkinson's disease (PD) expanded to add additional cohort. NEW YORK , April 26, 2018 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS)
View HTML
Toggle Summary Intra-Cellular Therapies Announces Positive Pre-NDA Meeting with FDA for Lumateperone for the Treatment of Schizophrenia
NEW YORK , March 13, 2018 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced that the Company had a positive pre-New Drug Application (NDA) meeting with
View HTML
Toggle Summary Intra-Cellular Therapies to Present at the Cowen and Company 38th Annual Health Care Conference
NEW YORK , March 08, 2018 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system ("CNS") disorders, today announced that Sharon Mates , Ph.D., Chief Executive Officer and Chairman, is
View HTML
Toggle Summary Intra-Cellular Therapies Reports Fourth Quarter and Full-Year 2017 Financial Results and Provides Corporate Update
NEW YORK , March 01, 2018 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced its financial results for the fourth quarter and year ended December 31,
View HTML
Toggle Summary Intra-Cellular Therapies to Host Fourth Quarter and Full Year 2017 Financial Results Conference Call and Webcast
NEW YORK , Feb. 22, 2018 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq:ITCI) a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced that it will host a conference call and live webcast discussion at 8:30 a.m.
View HTML
Toggle Summary UPDATE - Intra-Cellular Therapies to Present at RBC Capital Markets 2018 Global Healthcare Conference
NEW YORK , Feb. 15, 2018 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq:ITCI) a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced that Sharon Mates , Ph.D., Chief Executive Officer and Chairman, is scheduled
View HTML
Toggle Summary Intra-Cellular Therapies to Present at Upcoming Investor Conferences
NEW YORK , Feb. 07, 2018 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq:ITCI) a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced that it will present at the following upcoming investor conferences.
View HTML
Toggle Summary Intra-Cellular Therapies to Present at the 36th Annual J.P. Morgan Healthcare Conference
NEW YORK , Jan. 02, 2018 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced that Sharon Mates , Ph.D., Chief Executive Officer and Chairman, is scheduled
View HTML